|
Molecular properties generated using the CDK |
References |
1. Kiss LE et al.. (2010)
Pharmaceutical compounds. Patent number: WO2010074588 A2. Assignee: BIAL- PORTELA & Cª, S.A. Priority date: 24/12/2008. Publication date: 01/07/2010. |
2. Kiss LE, Learmonth DA, Da Costa Pereira Rosa CP, Gusmao De Norohna NR, Palma PNL, Soares Da Silva PMVA, Beliaev A. (2011)
Pharmaceutical compounds. Patent number: WO2010074588 A8. Assignee: BIAL-PORTELA and CA, S.A.. Priority date: 23/12/2008. Publication date: 06/10/2011. |
3. Lodola A, Castelli R, Mor M, Rivara S. (2015)
Fatty acid amide hydrolase inhibitors: a patent review (2009 - 2014). Expert Opin Ther Pat, 25 (11): 1247-66. [PMID:26413912] |
4. Sałaga M, Sobczak M, Fichna J. (2014)
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. Eur J Pharm Sci, 52: 173-9. [PMID:24275607] |
5. Ulugöl A. (2014)
The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J, 31 (2): 115-20. [PMID:25207181] |
6. van Esbroeck ACM, Janssen APA, Cognetta 3rd AB, Ogasawara D, Shpak G, van der Kroeg M, Kantae V, Baggelaar MP, de Vrij FMS, Deng H et al.. (2017)
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 356 (6342): 1084-1087. [PMID:28596366] |